Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Erythropoietin (EPO) in Preterm Infants 401-1250 Grams
NCT01203514Phase 3Completed
- Sponsor
- NICHD Neonatal Research Network
- Start
- Aug 1997
- Primary completion
- Aug 1998
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of erythropoietin in neonatal anemia (4 arms), sponsored by NICHD Neonatal Research Network. Primary endpoints: Erythrocyte transfusions in infants 401-1,000g birthweight and Blood transfusions in infants 1,001-1,250g birthweight. Started Aug 1997; status: completed.
02
Drugs
erythropoietin
03
Conditions
neonatal anemia
Beyond the preview
Go deeper on NCT01203514.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01203514.